非酒精性脂肪性肝病与非非酒精性脂肪性肝病肝细胞癌患者接受根治性治疗后的生存比较
该队列研究利用1991至2011年监测、流行病学和最终结果与医疗保险链接数据纳入17664例肝细胞癌患者,比较非酒精性脂肪性肝病(NAFLD)与非NAFLD病因患者接受根治性治疗后的生存。NAFLD组接受任何根治性治疗的可能性低47%(OR 0.53,P<.001),肝移植后中位生存更差(3.2年 vs 非NAFLD组,P=.01),但切除后生存更优(2.4年 vs 非NAFLD组,P<.001),射频消融无显著生存差异。
要点
- NAFLD肝细胞癌患者接受任何根治性治疗的可能性较非NAFLD病因低47%(OR 0.53,P<.001)。
- NAFLD组肝移植后中位生存3.2年,较非NAFLD组更差(P=.01)。
- NAFLD组切除后中位生存2.4年,较非NAFLD组更优(P<.001),射频消融无显著差异。
核心结论
- 与非NAFLD病因相比,NAFLD肝细胞癌患者肝移植后生存更差,但切除后生存更优,尤其在无肝硬化时。
- NAFLD并非肝移植、切除或射频消融后死亡的独立预测因素。
研究设计与样本
- 利用1991至2011年监测、流行病学和最终结果与医疗保险链接数据构建的17664例确诊肝细胞癌患者队列。
- 比较NAFLD与非NAFLD病因(慢性丙型肝炎、慢性乙型肝炎、酒精性肝病)及按治疗方式分层的生存。
主要发现
- 队列以男性为主,年龄70(21-106)岁,无心血管疾病,有肝硬化但无失代偿、无转移性肝细胞癌或大肿瘤(>5 cm)。
- NAFLD肝细胞癌组以女性为主、年龄更大,心血管疾病、转移性肝细胞癌和大肿瘤更多,肝硬化和失代偿性肝病更少。
- NAFLD组接受任何根治性治疗的可能性较非NAFLD病因低47%(OR 0.53,P<.001)。
- NAFLD组肝移植后中位生存3.2年(范围0-12.9年),较非NAFLD组更差(P=.01)。
- NAFLD组切除后中位生存2.4年(范围0-12.0年),较非NAFLD组更优(P<.001);射频消融后各病因间无显著生存差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is expected to become a leading aetiology of hepatocellular carcinoma (HCC)-related mortality in the United States. HCC treatments with curative intent (OLT, orthotopic liver transplantation; resection; RFA, radiofrequency ablation) can improve survival in carefully selected patients. AIM: To compare survival after receipt of curative treatment for NAFLD and non-NAFLD-HCC aetiologies (HCV, chronic hepatitis C; HBV, chronic hepatitis B; ALD, alcoholic liver disease) and by treatment was performed. METHODS: A cohort of 17 664 patients was assembled using linked Surveillance, Epidemiology, and End Results and Medicare data from 1991 to 2011 with confirmed diagnosis of HCC. RESULTS: The cohort was mostly male, aged 70 (21-106) years, without cardiovascular disease, and had liver cirrhosis without decompensation, metastatic HCC or large tumour size (>5 cm). The NAFLD-HCC group was mostly female and older with more cardiovascular disease, metastatic HCC, and large tumour size and less cirrhosis and decompensated liver disease than the non-NAFLD-HCC groups. The NAFLD group was 47% less likely to receive any curative treatment as compared with non-NAFLD aetiologies (OR 0.53, P < .001). NAFLD-HCC had worse median survival after OLT (3.2, 0-12.9 years, P = .01) but had improved survival after resection (2.4, 0-12.0 years, P < .001) as compared with non-NAFLD-HCC. No significant survival differences existed for RFA by HCC aetiology. NAFLD was not an independent predictor of mortality after OLT, resection or RFA. CONCLUSION: Patients with NAFLD-HCC had worse survival after OLT but favourable survival after resection, particularly in the absence of cirrhosis, as compared with non-NAFLD-HCC aetiologies.
引用
- Wong CR, Njei B, Nguyen MH, et al. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017. PMID: 28960360. doi:10.1111/apt.14342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。